Saito Kumi, Kasai Toshiyuki, Nagura Yohko, Ito Hitomi, Kanazawa Motoyori, Fukudo Shin
Department of Behavioral Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.
Gastroenterology. 2005 Nov;129(5):1533-43. doi: 10.1053/j.gastro.2005.07.053.
BACKGROUND & AIMS: The corticotropin-releasing hormone receptor 1 mediates stress-induced changes in colonic motor activity and emotion. We tested the hypothesis that pretreatment with JTC-017, a specific corticotropin-releasing hormone receptor 1 antagonist, blocks colorectal distention-induced hippocampal noradrenaline release and visceral perception in rats. We also investigated whether pretreatment with JTC-017 blocks acute or chronic colorectal distention-induced adrenocorticotropic hormone release, anxiety, and stress-induced changes in colonic motility.
Rats were pretreated intrahippocampally with alpha-helical corticotropin-releasing hormone (1.25 microg/kg; vehicle), a nonspecific corticotropin-releasing hormone receptor antagonist, or intraperitoneally with JTC-017 (10 mg/kg). Hippocampal noradrenaline release after microdialysis and the frequency of abdominal contractions were measured in response to acute colorectal distention. Plasma adrenocorticotropic hormone levels, anxiety-related behavior, and stress-induced changes in colonic motility were evaluated after acute or chronic colorectal distention followed by exposure to an elevated plus maze.
Administration of alpha-helical corticotropin-releasing hormone or JTC-017 significantly attenuated hippocampal noradrenaline release and reduced the frequency of abdominal contractions induced by acute distention. In addition, JTC-017 significantly reduced plasma adrenocorticotropic hormone and anxiety after acute distention. After chronic distention, changes in plasma adrenocorticotropic hormone and anxiety were not significant because of habituation. In contrast, a significant increase in fecal pellet output during the elevated plus maze was observed after chronic distention. This increase in fecal pellet output was blocked by pretreatment with JTC-017.
Our results suggest that JTC-017, a specific corticotropin-releasing hormone receptor 1 antagonist, attenuates hippocampal noradrenaline release, visceral perception, adrenocorticotropic hormone release, and anxiety after acute colorectal distention in rats. In addition, JTC-017 blocks stress-induced changes in colonic motility after chronic colorectal distention in rats.
促肾上腺皮质激素释放激素受体1介导应激引起的结肠运动活性和情绪变化。我们检验了以下假设:用特异性促肾上腺皮质激素释放激素受体1拮抗剂JTC - 017预处理可阻断结直肠扩张诱导的大鼠海马去甲肾上腺素释放和内脏感觉。我们还研究了JTC - 017预处理是否能阻断急性或慢性结直肠扩张诱导的促肾上腺皮质激素释放、焦虑以及应激引起的结肠运动变化。
大鼠海马内预先注射α - 螺旋促肾上腺皮质激素释放激素(1.25微克/千克;溶剂)、非特异性促肾上腺皮质激素释放激素受体拮抗剂,或腹腔注射JTC - 017(10毫克/千克)。微透析后测量海马去甲肾上腺素释放以及对急性结直肠扩张的腹部收缩频率。在急性或慢性结直肠扩张后,将大鼠置于高架十字迷宫中,评估血浆促肾上腺皮质激素水平、焦虑相关行为以及应激引起的结肠运动变化。
注射α - 螺旋促肾上腺皮质激素释放激素或JTC - 017可显著减弱海马去甲肾上腺素释放,并降低急性扩张诱导的腹部收缩频率。此外,JTC - 017可显著降低急性扩张后的血浆促肾上腺皮质激素水平和焦虑程度。慢性扩张后,由于适应作用,血浆促肾上腺皮质激素水平和焦虑的变化不显著。相反,慢性扩张后在高架十字迷宫中观察到粪便颗粒排出量显著增加。JTC - 017预处理可阻断这种粪便颗粒排出量的增加。
我们的结果表明,特异性促肾上腺皮质激素释放激素受体1拮抗剂JTC - 017可减弱大鼠急性结直肠扩张后的海马去甲肾上腺素释放、内脏感觉、促肾上腺皮质激素释放和焦虑。此外,JTC - 017可阻断大鼠慢性结直肠扩张后应激引起的结肠运动变化。